Common Thread in Recent Regulatory & Policy Discussions Considerations When Planning & Conducting Early Stage Trials
As pivotal clinical studies remain imperative to receiving approvals to bring new drugs to market, it’s encouraging and interesting to see a common thread passing through recent policy and regulatory discussions. This eBook shows close cooperation between major global regulatory entities and industry sponsors to adjust processes to maximize drug development efforts, speed up access to novel therapies, and help control development costs.
The enlightening eBook opens with a Q & A between Scrip and two leaders from CMIC Group:
Toshitaka Kawaratani, EVP Head of Consulting Division
Kazuhiro Fukata, Head of Regenerative Medicine Group
Inquiries about our services
Click below if you are interested in outsourcing your operations to us.
